Symbols

CTSO

Cytosorbents·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 0

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

Revenue Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CTSO

Cytosorbents Corporation

A leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification

Industry

Healthcare Equipment and Supplies

Established Date

04/25/2002

Listing Date

12/23/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

129

Fiscal Year Ends

12-31

Website

www.cytosorbents.com

Security Type

Common stock

Office address

305 College Road East Princeton New Jersey 08540

Business

Introduction

Cytosorbents Corporation was incorporated in Nevada on April 25, 2002. The company is a leader in the treatment of life-threatening diseases in intensive care units and cardiac surgery through blood purification. The company's proprietary blood purification technology is based on biocompatible, highly porous polymer beads that actively remove toxic substances from blood and other body fluids through pore capture and surface adsorption.

Company Financials

EPS

CTSO has released its 2025 Q4 earnings. EPS was reported at -0.07, versus the expected -0.05, missing expectations. The chart below visualizes how CTSO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CTSO has released its 2025 Q4 earnings report, with revenue of 9.23M, reflecting a YoY change of 0.91%, and net profit of -5.50M, showing a YoY change of 27.36%. The Sankey diagram below clearly presents CTSO's revenue sources and cost distribution.